Infliksimab: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
Tidak ada ringkasan suntingan |
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
||
| (12 revisi perantara oleh 3 pengguna tidak ditampilkan) | |||
Baris 1:
{{Penyangkalan medis}}
{{infobox drug
| Verifiedfields = changed
| verifiedrevid = 458271995
| type = mab
| image = Infliximab_structure2.jpg
| width =
| alt =
| caption =
<!-- Monoclonal antibody data -->
| mab_type = mab
| source = xi/o
| target = ''Tumor necrosis factors'' (TNF)
<!-- Clinical data -->
| pronounce =
| tradename = Remicade
| Drugs.com = {{drugs.com|monograph|infliximab}}
| MedlinePlus = a604023
| DailyMedID = Infliximab
| pregnancy_AU = C
| pregnancy_AU_comment = <ref name="Drugs.com pregnancy">{{cite web | title=Infliximab Use During Pregnancy | website=Drugs.com | date=2 July 2019 | url=https://www.drugs.com/pregnancy/infliximab.html | access-date=13 August 2020 | archive-date=30 November 2020 | archive-url=https://web.archive.org/web/20201130151454/https://www.drugs.com/pregnancy/infliximab.html | url-status=live }}</ref>
| pregnancy_category=
| routes_of_administration = [[Infus|Intravena]], [[penyuntikan subkutan|subkutan]]
| class =
| ATC_prefix = L04
| ATC_suffix = AB02
| ATC_supplemental =
| biosimilars = infliximab-abda,<ref name="Renflexis FDA approval" /> infliximab-axxq,<ref name="Avsola FDA approval" /> infliximab-dyyb,<ref name="Inflectra FDA approval" /> infliximab-qbtx,<ref name="Ixifi FDA approval" /> Avsola,<ref name="Avsola FDA approval" /> Flixabi,<ref name="Flixabi EPAR" /> Inflectra,<ref name="Inflectra FDA approval" /><ref name="CA 2016 Highlights" /> Ixifi,<ref name="Ixifi FDA approval" /> Remsima,<ref name="CA 2016 Highlights" /> Renflexis,<ref name="Renflexis FDA approval" /><ref>{{cite web | title=Arthritis | website=[[Health Canada]] | date=8 May 2018 | url=https://www.canada.ca/en/services/health/drug-health-products/drug-medical-device-highlights-2017/approved-drugs/arthritis.html | access-date=13 April 2024}}</ref><ref>{{cite web | title=Regulatory Decision Summary for Renflexis | website=Drug and Health Products Portal | date=1 December 2017 | url=https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS00305 | access-date=13 April 2024}}</ref> Zessly, Zymfentra<ref name="Zymfentra PR" />
<!-- Legal status -->
| legal_AU = S4
| legal_AU_comment =
| legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment =
| legal_CA = Rx-only
| legal_CA_comment = / Schedule D<ref>{{cite web | title=Health product highlights 2021: Annexes of products approved in 2021 | website=[[Health Canada]] | date=3 August 2022 | url=https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-product-highlights-2021/appendices.html | access-date=25 March 2024 | archive-date=25 March 2024 | archive-url=https://web.archive.org/web/20240325234307/https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-product-highlights-2021/appendices.html | url-status=live }}</ref><ref>{{cite web | title=Regulatory Decision Summary for Remsima SC | website=Drug and Health Products Portal | date=15 February 2024 | url=https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1708630999500 | access-date=2 April 2024 | archive-date=2 April 2024 | archive-url=https://web.archive.org/web/20240402033003/https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1708630999500 | url-status=live }}</ref><ref name="CA 2016 Highlights">{{cite web | title=Health Canada New Drug Authorizations: 2016 Highlights | website=[[Health Canada]] | date=14 March 2017 | url=https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-canada-new-drug-authorizations-2016-highlights.html | access-date=7 April 2024 | archive-date=7 April 2024 | archive-url=https://web.archive.org/web/20240407045431/https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-canada-new-drug-authorizations-2016-highlights.html | url-status=live }}</ref>
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE_comment =
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment =
| legal_UK = POM
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment = <ref name="Remicade FDA label">{{cite web | title=Remicade- infliximab injection, powder, lyophilized, for solution | website=DailyMed | date=8 April 2022 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0a046c1-056d-45a9-bfd9-13b47c24f257 | access-date=22 May 2024}}</ref><ref>{{cite web | title=Avsola- infliximab-axxq injection, powder, lyophilized, for solution | website=DailyMed | date=7 April 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de34bcb7-b524-45c8-9181-61c6f48d540e | access-date=22 May 2024}}</ref><ref>{{cite web | title=Inflectra- infliximab-dyyb injection, powder, lyophilized, for solution | website=DailyMed | date=5 April 2024 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37eaca10-d812-48bc-8b8e-b836bfa9968f | access-date=22 May 2024}}</ref><ref>{{cite web | title=Renflexis- infliximab injection, powder, lyophilized, for solution | website=DailyMed | date=26 January 2023 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3827e1be-f328-45f7-b113-311b57039f8c | access-date=22 May 2024}}</ref><ref>{{cite web | title=Zymfentra- infliximab-dyyb injection | website=DailyMed | date=2 May 2024 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=93a193ab-9f96-4da6-aa7c-31212e81879a | access-date=22 May 2024}}</ref>
| legal_EU = Rx-only
| legal_EU_comment = <ref name="Remicade EPAR" /><ref name="Flixabi EPAR" /><ref name="Remsima EPAR" /><ref name="Inflectra EPAR" /><ref name="Zessly EPAR" />
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_UN_comment =
| legal_status = <!--For countries not listed above-->
<!-- Pharmacokinetic data -->
| bioavailability = 92% (IV, jika 8% tersisa di dalam alat suntik
| protein_bound =
| metabolism = sistem retikuloendotelium
| metabolites =
| onset =
| elimination_half-life = 9,5 hari
| duration_of_action =
| excretion =
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 170277-31-3
| CAS_supplemental =
| PubChem =
| IUPHAR_ligand =
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00065
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = B72HH48FLU
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02598
| ChEBI_Ref =
| ChEBI =
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201581
| NIAID_ChemDB =
| PDB_ligand =
| synonyms =
<!-- Chemical and physical data -->
| IUPAC_name =
| C=6428 | H=9912 | N=1694 | O=1987 | S=46
| SMILES =
| StdInChI =
| StdInChI_comment =
| StdInChIKey =
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}}
'''Infliksimab''' merupakan sediaan injeksi [[antibodi monoklonal|antibodi]] dengan nama dagang [[Remicade]]®.<ref>{{Cite journal|last=Baert|first=Filip|last2=Noman|first2=Maja|last3=Vermeire|first3=Severine|last4=Van Assche|first4=Gert|last5=D' Haens|first5=Geert|last6=Carbonez|first6=An|last7=Rutgeerts|first7=Paul|date=2003-02-13|title=Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease|url=http://www.nejm.org/doi/abs/10.1056/NEJMoa020888|journal=New England Journal of Medicine|language=en|volume=348|issue=7|pages=601–608|doi=10.1056/NEJMoa020888|issn=0028-4793}}</ref> Infliximab disetujui untuk penggunaan medis berbagai penyakit [[radang]] yang disebabkan oleh sistem imun pada tahun 1998 oleh [[Badan Pengawas Obat dan Makanan Amerika Serikat|badan pengawas obat dan makanan Amerika]] (dalam bahasa inggris: ''Food and Drug Administration)'' atau FDA seperti [[penyakit Crohn]], [[kolitis ulseratif]], [[Rheumatoid Arthritis|rheumatoid arthritis]],[[spondilitis ankilosa]], [[psoriasis arthritis]] dan [[plak psoriasis]].<ref name=":0">{{Cite book|last=Fatima|first=Rawish|last2=Bittar|first2=Khaled|last3=Aziz|first3=Muhammad|date=2024|url=http://www.ncbi.nlm.nih.gov/books/NBK500021/|title=Infliximab|location=Treasure Island (FL)|publisher=StatPearls Publishing|pmid=29763197}}</ref>
Pemberian infliximab dilakukan melalui rute injeksi [[Infus|intravena]] atau [[subkutan]].<ref name=":0" /> Tersedia dalam serbuk terliofilisasi untuk rekonstitusi, dosis 100mg/vial untuk injeksi atau infus setelah direkonstitusi dan 120mg/mL dalam pena suntik dosis tunggal untuk injeksi subkutan.<ref name=":0" />
Baris 24 ⟶ 125:
== Referensi ==
<references />
[[Kategori:Penghambat faktor nekrosis tumor
[[Kategori:Antibodi monoklonal]]
[[Kategori:Obat Esensial Organisasi Kesehatan Dunia]]
Baris 30 ⟶ 131:
[[Kategori:Obat yang dikembangkan oleh Schering-Plough]]
[[Kategori:Obat yang dikembangkan oleh Merck & Co.]]
[[Kategori:
[[Kategori:Imunologi]]
[[Kategori:Protein rekayasa]]
| |||